Research graph
References from Bridging to systemic therapy: PSMA-PET-based early and repetitive stereotactic body radiotherapy for nodal and bone oligo-recurrent prostate cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Improved survival of patients with newly diagnosed oligometastatic prostate cancer through intensified multimodal treatment
10.3389/fonc.2024.1475914 · 2024 · External reference
The evolutionary history of lethal metastatic prostate cancer
10.1038/nature14347 · 2015 · External reference
Meta-analysis of randomized trials in cancer of the prostate MARCAP Consortium investigators. Local failure events in prostate cancer treated with radiotherapy: a pooled analysis of 18 randomized trials from the meta-analysis of randomized trials in cancer of the prostate consortium (LEVIATHAN)
10.1016/j.eururo.2022.07.011 · 2022 · External reference
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer
10.1038/nm.1944 · 2009 · External reference
Clinical and genomic differences between advanced molecular imaging-detected and conventional imaging-detected metachronous oligometastatic castration-sensitive prostate cancer
10.1016/j.eururo.2023.04.025 · 2023 · External reference
Abiraterone for prostate cancer not previously treated with hormone therapy
10.1056/nejmoa1702900 · 2017 · External reference
Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer
10.1056/nejmoa1704174 · 2017 · External reference
Predictors of recurrence after metastasis-directed therapy in oligorecurrent prostate cancer following radical prostatectomy
10.1016/j.euo.2023.02.010 · 2023 · External reference
More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT
10.1967/s002449910952 · 2019 · External reference
Review of prospective trials assessing the role of stereotactic body radiation therapy for metastasis-directed treatment in oligometastatic genitourinary cancers
10.1016/j.euo.2022.09.007 · 2023 · External reference
Radiotherapy concepts for spinal metastases-results from an online survey among radiation oncologists of the German Society for Radiation Oncology
10.1007/s00066-023-02082-w · 2024 · External reference
Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial
10.1200/jco.2017.75.4853 · 2018 · External reference
Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial
10.1016/j.eururo.2018.06.004 · 2018 · External reference
Stereotactic body radiotherapy for oligometastatic prostate cancer detected via prostate-specific membrane antigen positron emission tomography
10.1016/j.euo.2018.04.017 · 2018 · External reference
Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial
10.1001/jamaoncol.2020.0147 · 2020 · External reference
OLIGOPELVIS GETUG P07, a multicenter phase II trial of combined high-dose salvage radiotherapy and hormone therapy in oligorecurrent pelvic node relapses in prostate cancer
10.1016/j.eururo.2021.06.010 · 2021 · External reference
Curative-intent metastasis-directed therapies for molecularly-defined oligorecurrent prostate cancer: a prospective phase II trial testing the oligometastasis hypothesis
10.1016/j.eururo.2021.02.031 · 2021 · External reference
UK consensus on normal tissue dose constraints for stereotactic radiotherapy
10.1016/j.clon.2017.09.007 · 2018 · External reference
ACR-ASTRO practice parameter for communication: radiation oncology
10.1097/coc.0000000000000707 · 2020 · External reference
ACR-ASTRO practice parameter for the performance of stereotactic body radiation therapy
10.1097/coc.0000000000000706 · 2020 · External reference
Organ at risk dose constraints in SABR: a systematic review of active clinical trials
10.1016/j.prro.2021.03.005 · 2021 · External reference
Dose prescription for stereotactic body radiotherapy: general and organ-specific consensus statement from the DEGRO/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery
10.1007/s00066-024-02254-2 · 2024 · External reference
Early and repetitive novel-tracer PET-guided stereotactic body radiotherapy for nodal oligorecurrent prostate cancer after definitive first-line therapy
10.1007/s00066-024-02304-9 · 2025 · External reference
STROBE Initiative. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies
10.1016/s0140-6736(07)61602-x · 2007 · External reference
Progression-free survival in patients with 68Ga-PSMA-PET-directed SBRT for lymph node oligometastases
10.1080/0284186x.2021.1955970 · 2021 · External reference
Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: interim outcomes of a prospective clinical trial
10.1002/ijc.32509 · 2020 · External reference
Oligorecurrent prostate cancer and stereotactic body radiotherapy: where are we now? A systematic review and meta-analysis of prospective studies
10.1016/j.euros.2021.02.008 · 2021 · External reference
Salvage stereotactic radiotherapy for nodal oligo-recurrent prostate cancer: a systematic review and meta-analysis of randomized controlled trials
10.1016/j.clgc.2024.102239 · 2024 · External reference
The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer
10.1007/s00259-014-2949-6 · 2015 · External reference
The diagnostic role of 18F-choline, 18F-fluciclovine and 18F-PSMA PET/CT in the detection of prostate cancer with biochemical recurrence: a meta-analysis
10.3389/fonc.2021.684629 · 2021 · External reference
68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography for prostate cancer: a systematic review and meta-analysis
10.1016/j.euf.2016.11.002 · 2018 · External reference
Metaanalysis of 68Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology
10.2967/jnumed.118.219501 · 2019 · External reference
Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis
10.1016/j.eururo.2019.01.049 · 2020 · External reference
PSMA-targeted radiotracers versus 18F fluciclovine for the detection of prostate cancer biochemical recurrence after definitive therapy: a systematic review and meta-analysis
10.1148/radiol.2020191689 · 2020 · External reference
Performance of [68Ga] Ga-PSMA 11 PET for detecting prostate cancer in the lymph nodes before salvage lymph node dissection: a systematic review and meta-analysis
10.1038/s41391-019-0156-z · 2020 · External reference
68Ga-prostate-specific membrane antigen (psma) positron emission tomography (pet) in prostate cancer: a systematic review and meta-analysis
10.1590/s1677-5538.ibju.2019.0817 · 2021 · External reference
A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with 18F-DCFPyL in prostate cancer patients (OSPREY)
10.1097/ju.0000000000001698 · 2021 · External reference
Metastasis-directed therapy (SBRT) guided by PET-CT 18F-choline versus PET-CT 68Ga-PSMA in castration-sensitive oligorecurrent prostate cancer: a comparative analysis of effectiveness
10.1016/j.clgc.2020.08.002 · 2021 · External reference
Radiation therapy in the definitive management of oligometastatic prostate cancer: the Johns Hopkins experience
10.1016/j.ijrobp.2019.08.008 · 2019 · External reference
Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis
10.1007/s00066-019-01523-9 · 2020 · External reference
Prospective study of endogenous testosterone recovery following neoadjuvant hormonal blockade and radical prostatectomy in high-risk prostate cancer patients
10.1093/jsxmed/qdaf164 · 2025 · External reference
Prostate cancer and elective nodal radiation therapy for cN0 and pN0-a never ending story? Recommendations from the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO)
10.1007/s00066-023-02193-4 · 2024 · External reference
Whole-pelvic irradiation with boost to involved nodes and prostate in node-positive prostate cancer-long-term data from the prospective PLATIN-2 trial
10.1007/s00066-023-02129-y · 2024 · External reference
Early toxicity of a phase 2 trial of combined salvage radiation therapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer (OLIGOPELVIS GETUG P07)
10.1016/j.ijrobp.2018.12.020 · 2019 · External reference
Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer: an investigation of 117 pelvic lymph nodes
10.1007/s00066-021-01871-5 · 2022 · External reference
Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy
10.1007/s00066-020-01629-5 · 2020 · External reference
PSMA-guided metastases directed therapy for bone castration sensitive oligometastatic prostate cancer: a multi-institutional study
10.1007/s10585-022-10157-8 · 2022 · External reference
Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V–STORM): a phase 2, open-label, randomised controlled trial
10.1016/s1470-2045(25)00197-4 · 2025 · External reference
Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance
10.1007/s12032-021-01518-6 · 2021 · External reference
Comparative analysis of lymph node-only vs. bone-only metastasis-directed radiation therapy in oligorecurrent prostate cancer
10.1016/j.ijrobp.2025.06.2720 · 2025 · External reference
Systemic and tumor-directed therapy for oligorecurrent metastatic prostate cancer (SATURN): Primary endpoint results from a phase 2 clinical trial
10.1016/j.eururo.2024.01.021 · 2024 · External reference
ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial
10.1016/s1470-2045(24)00730-7 · 2025 · External reference
PERSIAN trial: Early results from a randomized phase II trial testing apalutamide and stereotactic body radiation therapy for low-burden, metastatic, hormone-sensitive prostate cancer
10.1200/jco.2025.43.5_suppl.160 · 2025 · External reference
ARCHES: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer
10.1200/jco.19.00799 · 2019 · External reference
Apalutamide for metastatic, castration-sensitive prostate cancer
10.1056/nejmoa1903307 · 2019 · External reference
Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial
10.1200/jco-24-01798 · 2024 · External reference
The efficacy of abiraterone in metastatic hormone-sensitive prostate cancer: a stratified meta-analysis based on subgroups of low or high disease volume and reconstructed individual patient data
10.1080/14737140.2025.2522981 · 2025 · External reference
Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer
10.1056/nejmoa2214122 · 2023 · External reference
Should we redefine the Phoenix criteria for biochemical recurrence after primary radiotherapy
10.1097/mou.0000000000001313 · 2025 · External reference
Unresolved reference
2026 · External reference
Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy
10.1097/01.ju.0000113794.34810.d0 · 2004 · External reference
Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organization for Research and Treatment of Cancer (EORTC) trial 30891
10.1200/jco.2005.04.7423 · 2006 · External reference
Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomized, multicenter, non-blinded, phase 3 trial
10.1016/s1470-2045(16)00107-8 · 2016 · External reference
Radiotherapy in oligometastatic prostate cancer-a pattern of care survey among members of the German Society for Radiation Oncology (DEGRO)
10.1007/s00066-022-01925-2 · 2022 · External reference
